Journal of Substance Abuse Treatment

Papers
(The TQCC of Journal of Substance Abuse Treatment is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine93
Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-1976
Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic74
A clash of epidemics: Impact of the COVID-19 pandemic response on opioid overdose66
A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder64
Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-1962
Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine62
Clinician perspectives on methadone service delivery and the use of telemedicine during the COVID-19 pandemic: A qualitative study56
Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A national qualitative study52
Implementation of emergency department–initiated buprenorphine for opioid use disorder in a rural southern state49
Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings49
A systematic review of stigma interventions for providers who treat patients with substance use disorders45
Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-1943
Online digital recovery support services: An overview of the science and their potential to help individuals with substance use disorder during COVID-19 and beyond42
Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-1941
Telehealth sustains patient engagement in OUD treatment during COVID-1940
Peer recovery coaches in general medical settings: Changes in utilization, treatment engagement, and opioid use39
COVID-19-related treatment service disruptions among people with single- and polysubstance use concerns39
Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island38
Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?36
Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms35
Impacts of COVID-19 on residential treatment programs for substance use disorder35
The application of digital health to the assessment and treatment of substance use disorders: The past, current, and future role of the National Drug Abuse Treatment Clinical Trials Network34
Appointment wait-times and arrival for patients at a low-barrier access addiction clinic34
The provision of counseling to patients receiving medications for opioid use disorder: Telehealth innovations and challenges in the age of COVID-1933
Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study33
Increased flexibility in methadone take-home scheduling during the COVID-19 pandemic: Should this practice be incorporated into routine clinical care?33
Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems32
“Now hospital leaders are paying attention”: A qualitative study of internal and external factors influencing addiction consult services32
Motivational interviewing and culture for urban Native American youth (MICUNAY): A randomized controlled trial31
COVID-19 and overdose prevention: Challenges and opportunities for clinical practice in housing settings31
Feasibility and early experience of a novel multidisciplinary alcohol-associated liver disease clinic31
Adolescent substance use: Challenges and opportunities related to COVID-1929
Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine28
Family involvement in treatment and recovery for substance use disorders among transition-age youth: Research bedrocks and opportunities28
Digital delivery of a contingency management intervention for substance use disorder: A feasibility study with DynamiCare Health27
Gender disparities in access and retention in outpatient methadone treatment for opioid use disorder in low-income urban communities27
A scoping review of alcohol, tobacco, and other drug use treatment interventions for sexual and gender minority populations27
Acute and extended exposure to episodic future thinking in a treatment seeking addiction sample: A pilot study26
Prevalence of documented alcohol and opioid use disorder diagnoses and treatments in a regional primary care practice-based research network26
Patterns of substance use before and after hospitalization among patients seen by an inpatient addiction consult service: A latent transition analysis26
Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic26
Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders26
Experiences of racial discrimination in the medical setting and associations with medical mistrust and expectations of care among black patients seeking addiction treatment25
Outreach to people who survive opioid overdose: Linkage and retention in treatment25
Substance use disorder treatment services for pregnant and postpartum women in residential and outpatient settings25
Treatment barriers among individuals with co-occurring substance use and mental health problems: Examining gender differences25
Difficult binds: A systematic review of facilitators and barriers to treatment among mothers with substance use disorders24
How emergency department visits for substance use disorders have evolved during the early COVID-19 pandemic24
Down the drain: Reconsidering routine urine drug testing during the COVID-19 pandemic24
One year of methadone maintenance treatment in a fentanyl endemic area: Safety, repeated exposure, retention, and remission24
Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis24
“You have to take this medication, but then you get punished for taking it:” lack of agency, choice, and fear of medications to treat opioid use disorder across the perinatal period24
Experiences of stigma among individuals in recovery from opioid use disorder in a rural setting: A qualitative analysis24
The impact of COVID-19 on substance use disorder treatment in California: Service providers' perspectives23
A chance to do it better: Methadone maintenance treatment in the age of Covid-1923
Adaptations to jail-based buprenorphine treatment during the COVID-19 pandemic23
Racial/ethnic and gender differences in receipt of brief intervention among patients with unhealthy alcohol use in the U.S. Veterans Health Administration22
A pilot randomized clinical trial of mindfulness-oriented recovery enhancement as an adjunct to methadone treatment for people with opioid use disorder and chronic pain: Impact on illicit drug use, he22
Engaging the justice system to address the opioid crisis: The Justice Community Opioid Innovation Network (JCOIN)22
Lessons from COVID 19: Are we finally ready to make opioid treatment accessible?22
Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder22
Predictors of premature treatment termination in a large residential addiction medicine program22
Hospitalization outcomes of people who use drugs: One size does not fit all21
Low-barrier buprenorphine during the COVID-19 pandemic: A rapid transition to on-demand telemedicine with wide-ranging effects21
Psychological treatment for methamphetamine use and associated psychiatric symptom outcomes: A systematic review21
Falling between two systems of care: Engaging families, behavioral health and the justice systems to increase uptake of substance use treatment in youth on probation21
“A good mother”: Impact of motherhood identity on women's substance use and engagement in treatment across the lifespan21
Buprenorphine waiver uptake among nurse practitioners and physician assistants: The role of existing waivered prescriber supply21
Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder21
Patient-centered care's relationship with substance use disorder treatment utilization21
COVID-19 innovations in medication for addiction treatment at a Skid Row syringe exchange20
Is necessity also the mother of implementation? COVID-19 and the implementation of evidence-based treatments for opioid use disorders20
Healthcare utilization patterns among persons who use drugs during the COVID-19 pandemic20
Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs20
A feasibility study providing substance use treatment in the Black church20
A smartphone-smartcard platform for contingency management in an inner-city substance use disorder outpatient program20
Mobile methadone medication units: A brief history, scoping review and research opportunity20
With crisis comes opportunity: Unanticipated benefits resulting from pivots to take-home naloxone (THN) programs during the COVID-19 pandemic19
Leveraging digital tools to support recovery from substance use disorder during the COVID-19 pandemic response19
“No home to take methadone to”: Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston19
A collision of crises: Addressing an HIV outbreak among people who inject drugs in the midst of COVID-1919
Changes in methadone take-home dosing before and after COVID-1919
Adapting methadone inductions to the fentanyl era19
Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 201618
Integrated substance use and prenatal care delivery in the era of COVID-1918
Adoption of telemedicine services by substance abuse treatment facilities in the U.S.18
Experiences of stigma in hospitals with addiction consultation services: A qualitative analysis of patients' and hospital-based providers' perspectives18
Massachusetts Justice Community Opioid Innovation Network (MassJCOIN)18
Revising our attitudes towards agonist medications and their diversion in a time of pandemic17
Differential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder17
Commentary on the impact of the COVID-19 pandemic on opioid use disorder treatment among Indigenous communities in the United States and Canada17
Racial differences in overdose training, naloxone possession, and naloxone administration among clients and nonclients of a syringe services program17
Pilot trial investigating a brief behavioral economic intervention as an adjunctive treatment for alcohol use disorder17
Substance use treatment in Appalachian Tennessee amid COVID-19: Challenges and preparing for the future17
Characterizing variability in state-level regulations governing opioid treatment programs17
Contingency management for treatment attendance: A meta-analysis17
Legalization of cannabis use in Canada: Impacts on the cannabis use profiles of youth seeking services for substance use16
Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: Provider perspectives16
The Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support (TCN-PATHS): A hybrid type-1 effectiveness trial of enhanced primary care to improve opioid use d16
Geographic access to buprenorphine prescribers for patients who use public transit16
“In their mind, they always felt less than”: The role of peers in shifting stigma as a barrier to opioid use disorder treatment retention16
Providing addiction services during a pandemic: Lessons learned from COVID-1916
Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV16
The intersection of race and opioid use disorder treatment: A quantitative analysis16
Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series16
Something to despair: Gender differences in adverse childhood experiences among rural patients16
A systematic literature review of clinical trials and therapeutic applications of ibogaine16
Sharp decline in hospital and emergency department initiated buprenorphine for opioid use disorder during COVID-19 state of emergency in California16
COVID-19 and treating incarcerated populations for opioid use disorder16
Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: An adaptation to the COVID-19 emergency15
Expanding buprenorphine treatment to people experiencing homelessness through a mobile, multidisciplinary program in an urban, underserved setting15
Research on substance use disorders during the COVID-19 pandemic15
Did drug use increase following COVID-19 relaxation of methadone take-out regulations? 2020 was a complicated year15
Considering the harms of our habits: The reflexive urine drug screen in opioid use disorder treatment15
Comparing intentions to reduce substance use and willingness to seek help among transgender and cisgender participants from the Global Drug Survey15
Digital recovery networks: Characterizing user participation, engagement, and outcomes of a novel recovery social network smartphone application14
“I have to be around people that are doing what I'm doing”: The importance of expanding the peer recovery coach role in treatment of opioid use disorder in the face of COVID-19 health disparities14
Unprecedented need and recommendations for harnessing data to guide future policy and practice for opioid use disorder treatment following COVID-1914
New kid on the block: An investigation of the physical, operational, personnel, and service characteristics of recovery community centers in the United States14
A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder14
Telemedicine works for treating substance use disorder: The STAR clinic experience during COVID-1914
The impact of trauma characteristics on post-traumatic stress disorder and substance use disorder outcomes across integrated and substance use treatments14
The impact of naturalistic cannabis use on self-reported opioid withdrawal14
Peer recovery services for persons returning from prison: Pilot randomized clinical trial investigation of SUPPORT14
Use of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemic14
Personal, provider and system level barriers and enablers for hepatitis C treatment in the era of direct-acting antivirals: Experiences of patients who inject drugs accessing treatment in general prac14
Racial/ethnic disparities in the availability of hospital based opioid use disorder treatment14
Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-1914
The role of perceived treatment need in explaining racial/ethnic disparities in the use of substance abuse treatment services13
Overdose deaths from nonprescribed prescription opioids, heroin, and other synthetic opioids in Medicare beneficiaries13
Adolescent SBIRT implementation: Generalist vs. Specialist models of service delivery in primary care13
Effect of a web-based relapse prevention program on abstinence among Japanese drug users: A pilot randomized controlled trial13
Health center implementation of telemedicine for opioid use disorders: A qualitative assessment of adopters and nonadopters13
Exploring first responders' perceptions of medication for addiction treatment: Does stigma influence attitudes?13
Facilitators and barriers to post-overdose service delivery in Rhode Island emergency departments: A qualitative evaluation13
Competing risks of women and men who use fentanyl: “The number one thing I worry about would be my safety and number two would be overdose”13
Parental status and characteristics of women in substance use treatment services: Analysis of electronic patient records13
Psychosocial intervention utilization and substance abuse treatment outcomes in a multisite sample of individuals who use opioids13
Kentucky Women's Justice Community Opioid Innovation Network (JCOIN): A type 1 effectiveness-implementation hybrid trial to increase utilization of medications for opioid use disorder among justice-in13
The “Women and Trauma” study and its national impact on advancing trauma specific approaches in community substance use treatment and research13
“They went down that road, and they get it”: A qualitative study of peer support worker roles within perinatal substance use programs13
Caring for women with substance use disorders through pregnancy and postpartum during the COVID-19 pandemic: Lessons learned from psychology trainees in an integrated OBGYN/substance use disorder outp13
A pilot randomized clinical trial of Brief Behavioral Treatment for Insomnia to reduce problematic cannabis use among trauma-exposed young adults12
Health care-seeking experiences for people who inject drugs with hepatitis C: Qualitative explorations of stigma12
Feasibility and acceptability of a digital health intervention to promote engagement in and adherence to medication for opioid use disorder12
National trends in substance use treatment admissions for opioid use disorder among adults experiencing homelessness12
Alcohol screening and brief intervention in emergency departments: Review of the impact on healthcare costs and utilization12
Examining factors that shape use and access to diverted prescription opioids during an overdose crisis: A qualitative study in Vancouver, Canada12
The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth12
Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing12
Augmenting substance use treatment in the drug court: A pilot randomized trial of peer recovery support12
A Facebook intervention to address cigarette smoking and heavy episodic drinking: A pilot randomized controlled trial12
It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment12
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)12
Drug and alcohol treatment utilization and barriers among Black, American Indian/Alaskan Native, Latine, Asian/Pacific Islander/Native Hawaiian, and White adults: Findings from NESARC-III12
Use of an electronic pillbox to increase number of methadone take-home doses during the COVID-19 pandemic12
Hepatitis C cascade of care at an integrated community facility for people who inject drugs12
Help seeking behaviors of Latinos with substance use disorders who perceive a need for treatment: Substance abuse versus mental health treatment services12
A randomized clinical trial of smartphone self-managed recovery support services12
Recovering from substance use disorders during the early months of the COVID-19 pandemic: A mixed-methods longitudinal study of women in Kansas City12
Integrating harm reduction and clinical care: Lessons from Covid-19 respite and recuperation facilities12
Opioid overdose and inpatient care for substance use disorder care in Massachusetts12
Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges12
Using machine learning to identify predictors of imminent drinking and create tailored messages for at-risk drinkers experiencing homelessness11
From policy to practice: Pilot program increases access to medication for opioid use disorder in rural Colorado11
Parent SMART (Substance Misuse in Adolescents in Residential Treatment): Pilot randomized trial of a technology-assisted parenting intervention11
Perspectives on trauma and the design of a technology-based trauma-informed intervention for women receiving medications for addiction treatment in community-based settings11
Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada11
Community coalition and key stakeholder perceptions of the community opioid epidemic before an intensive community-level intervention11
Extended-release naltrexone for youth with opioid use disorder11
Mobile low-threshold buprenorphine integrated with infectious disease services11
Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic11
Increased availability of telehealth mental health and substance abuse treatment for peripartum and postpartum women: A unique opportunity to increase telehealth treatment11
The impact of COVID-19 on opioid treatment program (OTP) services: Where do we go from here?11
Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse11
Use of non–prescribed buprenorphine in the criminal justice system: Perspectives of individuals recently released from incarceration11
Views of barriers and facilitators to continuing methadone treatment upon release from jail among people receiving patient navigation services11
Exploring nonprescribed use of buprenorphine in the criminal justice system through qualitative interviews among individuals recently released from incarceration11
Bridge clinic buprenorphine program decreases emergency department visits11
Prescribed and non-prescribed gabapentin use among persons seeking inpatient opioid detoxification11
Benzodiazepine misuse in adults with alcohol use disorder: Prevalence, motives and patterns of use10
Healthcare utilization of individuals with substance use disorders following Affordable Care Act implementation in a California healthcare system10
Impact of COVID-19 on service delivery for an evidence-based behavioral treatment for families involved in the child welfare system10
Nicotine and cannabis vaping among adolescents in treatment for substance use disorders10
Characterizing trends in methamphetamine-related health care use when there is no ICD code for “methamphetamine use disorder”10
What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings10
Adaptation of contingency management for stimulant use disorder during the COVID-19 pandemic10
Improving retention across the OUD service cascade upon reentry from jail using Recovery Management Checkups-Adaptive (RMC-A) experiment10
Treatment admissions for opioids, cocaine, and methamphetamines among adolescents and emerging adults after legalization of recreational marijuana10
Cannabis use disorder among veterans: Comorbidity and mental health treatment utilization10
Initial testing of a computer-based simulation training module to support clinicians' acquisition of CBT skills for substance use disorder treatment10
From working on recovery to working in recovery: Employment status among a nationally representative U.S. sample of individuals who have resolved a significant alcohol or other drug problem10
Value of family involvement in substance use disorder treatment: Aligning clinical and financing priorities10
Substance use among women who are pregnant: Examining treatment completion by race and ethnicity10
A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic10
Substance use predictors of attendance among veterans in integrated PTSD and alcohol use disorder treatment10
A randomized trial of an integrated cognitive behavioral treatment protocol for adolescents receiving home-based services for co-occurring disorders10
Factors associated with psychotic symptoms among a sample of male prisoners with substance use disorder: A cross-sectional study10
Racial inequity in methadone dose at delivery in pregnant women with opioid use disorder10
Race, ethnicity, and emergency department post-overdose care10
0.065621852874756